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ABSTRACT
The regulated recruitment and differentiation of multipotent
bone marrow-derived cells (BMDCs) to sites of injury are
critical for efﬁcient wound healing. Previously we demon-
strated that sustained expression of HOXA3 both accelerated
wound healing and promoted angiogenesis in diabetic mice.
In this study, we have used green ﬂuorescent protein-posi-
tive bone marrow chimeras to investigate the effect of
HOXA3 expression on recruitment of BMDCs to wounds.
We hypothesized that the enhanced neovascularization
induced by HOXA3 is due to enhanced mobilization, recruit-
ment, and/or differentiation of BMDCs. Here we show that
diabetic mice treated with HOXA3 displayed a signiﬁcant
increase in both mobilization and recruitment of endothelial
progenitor cells compared with control mice. Importantly,
we also found that HOXA3-treated mice had signiﬁcantly
fewer inﬂammatory cells recruited to the wound compared
with control mice. Microarray analyses of HOXA3-treated
wounds revealed that indeed HOXA3 locally increased
expression of genes that selectively promote stem/progenitor
cell mobilization and recruitment while also suppressing
expression of numerous members of the proinﬂammatory
nuclear factor jB pathway, including myeloid differentiation
primary response gene 88 and toll-interacting protein. Thus
HOXA3 accelerates wound repair by mobilizing endothelial
progenitor cells and attenuating the excessive inﬂammatory
response of chronic wounds. STEM CELLS 2009; 27: 1654–1665
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
Tissue repair and regeneration require dramatic and coordi-
nated changes in cell behavior in both wound-resident cells at
the site of injury and in distant cells that respond to and are
recruited to the injured tissue. Cells within the skin, normally
homeostatic, respond to injury by increasing expression of
genes that induce mitosis, migration, and direct synthesis and
remodeling the extracellular matrix. This tightly regulated
process involves a ‘‘ramping up’’ of growth factor and cyto-
kine release followed by adult stem/progenitor cell mobiliza-
tion, migration, engraftment, and ﬁnally, differentiation in
response to injury. Studies investigating the genes involved in
this process have identiﬁed both transcription factors and
ligand/receptor pairs that have previously been implicated in
wound healing. Genes such as Hif-1a, Hoxa3, Cxcl12/Cxcr4,
and Vegf/Vegfr2 among others play a variety of roles in
wound repair and regeneration [1–5]; however, much of the
genetic control of adult stem and progenitor cell behavior dur-
ing wound repair and regeneration is largely unknown.
Angiogenesis is the growth of new blood vessels from
existing blood vessels, whereas vasculogenesis is the growth
of new blood vessels from stem or progenitor cells that are
presumably recruited from the bone marrow. Previously we
demonstrated that the transcription factor, HOXA3, signiﬁ-
cantly promotes angiogenesis/vasculogenesis during tissue
repair and regeneration and accelerates cutaneous wound heal-
ing in vivo [3]. In particular we demonstrated that transient
gene transfer of HOXA3 to skin wounds of diabetic mice
Author contributions: K.A.M.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript
writing, ﬁnal approval of manuscript; T.E.R.: collection and/or assembly of data, ﬁnal approval of manuscript; J.L.R.: collection and/or
assembly of data, data analysis and interpretation, ﬁnal approval of manuscript; A.C.P. and H.Y.C.: data analysis and interpretation, ﬁnal
approval of manuscript; D.M.Y.: ﬁnancial support, data analysis and interpretation, ﬁnal approval of manuscript; N.J.B.: conception and
design, data analysis and interpretation, manuscript writing, ﬁnal approval of manuscript.
Correspondence: Kimberly A. Mace, Ph.D., Healing Foundation Centre, University of Manchester, Oxford Road, Faculty of Life
Sciences, Michael Smith Building, Manchester M13 9PT, U.K.. Telephone: þ44-[0]-161-275-1700; e-mail: kimberly.mace@manchester.
ac.uk; or Nancy J. Boudreau, Ph.D., University of California, San Francisco, Surgical Research Laboratory, Box 1302, San Francisco,
California 94143-1302, USA. Telephone: þ1-415-206-6951; e-mail: nboudreau@sfghsurg.ucsf.edu Received October 19, 2008;
accepted for publication March 30, 2009; ﬁrst published online in STEM CELLS EXPRESS April 9, 2009; available online without subscrip-
tion through the open access option. V C AlphaMed Press 1066-5099/2009/$30.00/0 doi: 10.1002/stem.90
STEM CELLS 2009;27:1654–1665 www.StemCells.comresulted in the upregulation of target genes, such as Plaur,
Mmp14, and Cdc42, that are involved in extracellular matrix
remodeling and cell migration.
A number of recent studies have also suggested that
recruitment of bone marrow-derived cells (BMDCs) can
enhance tissue repair in ischemic and myocardial infarction
models, as well as in cutaneous wounds (recently reviewed in
Wu et al [6]). Both angiogenesis and vasculogenesis can be
improved in response to the presence of BMDCs in the
wound milieu (recently reviewed in Schatteman et al [7]).
Speciﬁcally, recruitment of multipotent mesenchymal stromal
cells (MSCs) and endothelial progenitor cells (EPCs) can dra-
matically enhance neovascularization, either through direct
incorporation and differentiation in the neovasculature, or by
functioning as perivascular support cells that produce addi-
tional factors that stimulate repair [8–10].
BMDCs are ﬁrst mobilized from the bone marrow and
enter circulation in response to signals from the wound.
Growth factors and cytokines such as VEGF and SDF-1/
CXCL12 have been strongly implicated as signals that medi-
ate this response [5, 11]. However, BMDCs consist of a heter-
ogeneous population that can play repressive as well as sup-
portive roles during wound healing. Over the past few
decades, studies on the effects of inﬂammation during wound
repair overwhelmingly support a model in which too many
inﬂammatory cells and/or their overstimulation can impede the
healing process [12–14]. Although mild inﬂammation early in
response to injury may enhance angiogenesis/vasculogenesis,
prolonged and/or excessive presence of leukocytes, activated
neutrophils, and macrophages in particular, are associated with
chronic wounds that have severely impaired healing [15, 16],
and may interfere with efﬁcient neovascularization.
Because many Hox genes have been found to play an im-
portant role in the regulation of blood stem cell proliferation
and differentiation (recently reviewed in Argiropoulos and
Humphries [17]), and the Hox-3 paralog group in particular
has been shown to promote neovascularization [3, 18, 19], we
hypothesized that HOXA3-augmented diabetic wound healing
may in part arise from its potential impact on BMDCs. This
could occur via modulation of BMDC mobilization, recruit-
ment, or differentiation of stem/progenitor cells, or any com-
bination of these processes during wound repair and regenera-
tion. Here we show that sustained expression of HOXA3 in
diabetic wounds is accompanied by speciﬁc transcriptional
changes in the wound microenvironment that modulate both
the quantity and type of BMDCs recruited to cutaneous
wounds, accelerating tissue repair.
MATERIALS AND METHODS
Mouse Strains and Bone Marrow Chimeras
All animals used in this study were housed in the University of
California San Francisco (UCSF) animal care facility, and the
UCSF Committee on Animal Research approved all procedures
on animals. Male diabetic (db/db) mice (B6.Cg-m
þ/þ Lepr
db/J;
Jackson Laboratory, Bar Harbor, ME, http://www.jax.org) and
heterozygous (db/þ) controls age 8-10 weeks were lethally irradi-
ated (10 Gy). Bone marrow was harvested from 8- to 10-week-
old female donor mice ubiquitously expressing enhanced green
ﬂuorescent protein (GFP) (C57BL/6-Tg(CAG-EGFP)1Osb/J;
Jackson Laboratory) by ﬂushing the femurs and tibiae with Dul-
becco’s modiﬁed Eagle’s medium. Bone marrow was passed
through a sterile 27-gauge needle and through a 70-lm nylon
mesh cell strainer (BD Biosciences, San Diego, http://
www.bdbiosciences.com) and rinsed once in phosphate-buffered
saline (PBS), and viable cells were counted. Chimeras were gen-
erated by injecting 10
6 viable cells into the retro-orbital plexus of
the male db/db or db/þ mice approximately 6 hours after irradia-
tion. Mice were maintained on antibiotic-treated water (Ditrim, 5
ml/200 ml) for 2 weeks, and allowed 4 weeks for reconstitution
before any further procedures were performed.
Wound Model and Methylcellulose-Mediated
Gene Transfer
Prior to wounding, blood glucose levels were measured after a
12-hour fast using a standard portable blood glucose meter and
GFP chimerism was measured by ﬂow cytometry as described
below. After conﬁrmation of hyperglycemia in db/db recipients
and GFP chimerism in all recipients, mice were wounded by
making an 8-mm full thickness excisional wound on the dorsum
as described previously [3]. Skin removed from the wound at this
time was used for day 0. For chimera studies, db/db mice were
randomly grouped into experimental and control groups (n ¼ 6-8
for each group), and heterozygous (db/þ) control groups (n ¼ 3-
4) for each time point (day 0, day 7, and day 14). For bone mar-
row and peripheral blood wound response quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) experiments,
two db/þ and two db/db mice were used for each time point (day
0 and day 4). For microarray experiments, four db/db mice were
used, split into two groups, one experimental (n ¼ 2) and one
control group (n ¼ 2), with skin from all four mice pooled for
two technical replicates at the day 0 time point. Two mice were
used from each group at day 4 for a total of four biological repli-
cates. In each study, experimental groups were treated with cyto-
megalovirus promoter-driven CMV-HOXA3 expression plasmid
and control groups were treated with vector control. Plasmids
were prepared as described previously [3], using 25 lg of DNA
per 0.8-cm diameter wound, mixed, and dried down in 1% methyl
cellulose to form a ﬂat pellet. Twenty-ﬁve micrograms was deter-
mined as the optimal amount of plasmid DNA to achieve maximal
expression, while minimizing toxicity, using a dose curve analysis
of 5, 15, 25, 35, and 50 lg, Western blot quantiﬁcation and qualita-
tive wound healing analysis. Plasmid pellets were applied directly
to the open wound at the time of wounding. Animals were housed
individually and wounds left undressed. Mice were anesthetized
prior to wounding with isoﬂurane gas (2%) in oxygen, and received
0.05 mg/kg buprenorphine subcutaneously at the time of wounding
followed by a second dose 12 hours later.
Immunohistochemistry
For the chimera studies, wounds were harvested at days 0, 7, and
14, incubated in formalin for 3 days, and embedded in parafﬁn.
Five-lm sections were cut, dried for at least 24 hours, and stored
at room temperature or processed immediately. Sections were
deparafﬁnized in three changes of xylenes, followed by ethanol
and methanol washes, and then rehydrated. Antigen retrieval was
performed by microwaving sections in sodium citrate buffer (10
mM Na citrate, 0.05% Tween 20, pH 6.0) for 20 minutes, fol-
lowed by standard immunoﬂuorescent detection. Rabbit anti-GFP
(Abcam, Cambridge, U.K., http://www.abcam.com) was used at a
dilution of 1:1000; rat anti-Cd45 (Invitrogen, Carlsbad, CA,
http://www.invitrogen.com), at 1:50; goat anti-Cd34 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com), at
1:100; rabbit anti-Cd29 (Abcam), at 1:250; and chicken anti-GFP
(Abcam), at 1:500. Primary antibodies were detected with combi-
nations of the following secondaries at 1:400: donkey anti-rabbit
Alexa555 or goat anti-rabbit Alexa 488, donkey anti-rat Alexa
488 or goat anti-rat Alexa 555, donkey anti-goat Cy5, and goat
anti-chicken Alexa 647, as appropriate.
Flow Cytometry
Blood samples were analyzed from chimeras prior to wounding
(GFP only) and on days 0, 4, 7, and 14, as follows:  200 llo f
blood from each mouse was collected using a cheek lancet
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com) into 50 ll of heparin solution, followed by ammonium chlo-
ride red blood cell (RBC) lysis and removal by centrifugation.
Cleared blood was then analyzed by ﬂow cytometry (LSR-II; BD
Biosciences) and accompanying DIVA software (BD Biosciences)
and FlowJo software (TreeStar, Inc., Ashland, OR, http://
www.treestar.com). Samples were incubated with the following
antibodies: anti-Cd34 Paciﬁc Blue (1:20), anti-Cd133 PE (1:50),
anti-Cxcr4 APC (1:20), anti-Cd45 PE-Cy7 (1:2000), and anti-
Cd117 PE-Cy5.5 (1:200) (eBioscience, San Diego, http://
www.ebioscience.com).
RNA Isolation and Quantitative RT-PCR
Murine skin/wounds were harvested at the speciﬁed time points
indicated and ﬂash-frozen on dry ice and stored at  80  Co r
stored in RNA later (Ambion, Austin, TX, http://www.ambion.
com) at 4  C. Tissue was then brieﬂy rinsed in RNAse-free PBS
(Ambion). RNA was isolated by tissue homogenization in Trizol
(Invitrogen) with a rotor-stater homogenizer (Omni International,
Marietta, GA, http://www.omni-inc.com). RNA was analyzed
using a UV spectrophotometer and gel electrophoresis and stored
at  80 C. One lg of total RNA was used in reverse transcription
reactions using random primers in a total volume of 25 ll. qRT-
PCRs were performed at least three times on each sample using
approximately 25 ng of template cDNA, Taqman probe/primer
pairs (Hoxa3, Ccl2, b-defensin [Defb15], Myd88, Tollip, and His-
tone2A & 18S as reference controls), and universal master mix
for each gene analyzed (Applied BioSystems, Foster City, CA,
http://www. appliedbiosystems.com) on an ABI Prism SDS 7000
or Step-One-Plus machine according to the manufacturer’s
instructions. Data were analyzed with SDS 7000 or Step-One-
Figure 1. Bone marrow-derived cell (BMDC) recruitment to diabetic wounds in GFP bone marrow chimeras is dramatically increased compared
with nondiabetic wounds. (A): Representative bone marrow chimerism ﬂow cytometry analysis of peripheral blood using non-GFP chimera sib-
lings as negative controls. (B): Representative day 7 wound section stained with hematoxylin and eosin is shown in the upper half of the panel.
A graphic of this section is shown in the lower half of the panel. Red cross-hatching represents the wound. Rectangles 1, 2, and 3 represent areas
near the wound boundary imaged using confocal microscopy to obtain average recruited BMDC number for each animal. Scale bar ¼ 1 mm.
(C): Relative number of BMDCs (normalized using DAPI-stained nuclei to account for cell density differences) recruited to the wound site in
unwounded nondiabetic controls (wt D0), unwounded diabetic (db D0), day 7 wounds from nondiabetic (wt D7) and diabetic (db D7) mice. As-
terisk indicates p < .05. (D): Representative images of DAPI staining and GFP immunoﬂuorescence of BMDCs in wound sections as shown in
(B) from nondiabetic (wt) and diabetic (db) mice at day 0 and day 7 following wounding. Scale bar ¼ 100 lm. Abbreviations: d, dermis, DAPI,
40,6-diamidino-2-phenylindole; db, diabetic; D0, day 0; D7, day 7; ep, epithelium, es, eschar, Freq, frequency; FSC-H, forward scatter height;
GFP, green ﬂuorescent protein; gr, granulation tissue; m, muscle; neg cntl, negative control; SSC-H, side scatter height; wt, wild type.
1656 Wound Recruitment of Bone Marrow-Derived CellsPlus companion software and Microsoft Excel (Microsoft, Red-
mond, WA, http://www.microsoft.com).
Microarray Analysis and Validation
Total RNA harvested from day 0, 4, and 7 wounds and universal
mouse reference RNA (Stratagene, La Jolla, CA, http://www.stra-
tagene.com) were ampliﬁed and labeled using the Amino Allyl
MessageAmp II kit with Cy5 and Cy3 dUTP (Ambion). Labeled
RNAs were then hybridized to murine whole genome expression
(MEEBO) arrays (Stanford University). Arrays were scanned and
analyzed using Stanford functional genomics facility scanner and
accompanying software (Agilent Technologies, Palo Alto, CA,
http://www.agilent.com). All arrays were inspected for hybridiza-
tion defects using MEEBO-speciﬁc quality plots from the Biocon-
ductor package arrayQuality [20], and print-tip loess normaliza-
tion was used to correct for any dye or spatial biases [21].
Differentially expressed genes were determined using a Student’s
t test (p < .05), followed by additional intensity and fold-change
ﬁltering (log-intensity > 8 and absolute fold-change > 1.5). Dif-
ferentially expressed genes were further analyzed for functional
groups using WebGestalt (http://bioinfo. vanderbilt.edu/webges-
talt) [22]. The minimum number of overrepresented genes was
set to 3, and a p value cutoff of .05 was used for Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathway and Gene Ontol-
ogy (GO) process identiﬁcation. Complete data ﬁles are available
at National Center for Biotechnology Information’s Gene Expres-
sion Omnibus [23] http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc¼GSE13324. Genes selected for validation and further
analyses were quantiﬁed using qRT-PCR on RNA from microar-
ray samples and at least two other samples collected
independently.
Statistical Analyses
Statistical signiﬁcance was determined using a Student’s t test for
experiments where control and experimental groups were being
compared, as noted in ﬁgures or text. Statistical signiﬁcance was
determined using analysis of variance, followed by a post hoc
Tukey’s test when more than two groups were being compared. A
p value of < .05 was considered signiﬁcant, unless otherwise
noted.
RESULTS
Recruitment of BMDCs to Wounds Is
Signiﬁcantly Increased in Diabetic Mice
Diabetic wounds in both rodent models and human patients
exhibit increased inﬂammation [24, 25]. However, recruitment
of total BMDCs to diabetic wounds, which contain stem/pro-
genitor cell types as well as inﬂammatory precursors, has not
been previously analyzed, although addition of mononuclear
bone marrow cells to diabetic wounds has been shown to
improve healing [26]. To compare recruitment of BMDCs in
diabetic and nondiabetic mice, we reconstituted lethally irradi-
ated mice (6 Lepr
db /  ‘‘db/db’’ diabetic mice and 4 Lepr
dbþ/ 
‘‘db/þ’’ nondiabetic littermate controls) with bone marrow
from donor mice ubiquitously expressing GFP driven by the
chicken b-actin promoter [27]. After 4 weeks of reconstitu-
tion, chimerism was analyzed by ﬂow cytometry (Fig. 1A),
with the mean percentage of GFP-positive cells in RBC-
cleared blood greater than 80% (82.07   4.05 SEM). Sections
through unwounded skin (day 0) and 8-mm full thickness
excisional wounds (day 7) of GFP chimeras were analyzed
with hematoxylin and eosin to obtain similar positions within
the wound tissue for further analysis. The day 7 time point
was selected as it represents the peak of angiogenesis, and is
well after the peak of the inﬂammatory phase, which occurs
at days 3-4. Parallel sections were then analyzed for GFP
þ
cells, relative to 40,6-diamidino-2-phenylindole (DAPI)-posi-
tive cells, in three separate areas near the wound edge to
obtain an average for each wound (Fig. 1B). Although there
is no signiﬁcant difference in BMDC numbers in the skin of
diabetic and nondiabetic mice prior to injury (day 0), there is
a dramatic increase in total BMDC wound recruitment to cu-
taneous wounds by 7 days after injury. Nondiabetic mice ex-
hibit an  3-fold increase in BMDCs in day 7 wounds com-
pared with day 0, whereas diabetic mice exhibit an  18-fold
increase in BMDCs in day 7 wounds compared with day 0
(Fig. 1C, 1D).
Sustained Expression of HOXA3 in Diabetic
Wounds Reduces the Number of
Recruited BMDCs
As we previously demonstrated an increase in neovasculariza-
tion due to wound-speciﬁc expression of CMV-HOXA3 [3],
we wished to test whether HOXA3 had any effect on recruit-
ment of BMDCs, which are known to play a role in this pro-
cess. We used GFP
þ bone marrow chimeras to enumerate and
identify BMDCs at different time points during the repair pro-
cess. Three groups of mice were wounded with 8-mm-diame-
ter full thickness excisional wounds as described previously
[3]: 6 diabetic (db/db) mice were treated with 25 lg CMV-
HOXA3 plasmid; 6 diabetic mice were treated with 25 lg
pcDNA3.1myc/his (empty vector), and 4 nondiabetic (db/þ)
mice were treated with 25 lg pcDNA3.1myc/his (empty vec-
tor), as this amount was determined to be optimal (see Mate-
rials and Methods for details). Nondiabetic mice were not
treated with CMV-HOXA3 as this has no observable effect on
wound healing [3]. Immunolocalization of total GFP
þ cells
revealed that at days 7 and 14 after wounding the number of
GFP
þ cells in db/db mice treated with CMV-HOXA3 was sig-
niﬁcantly reduced compared with vector control-treated mice
(Fig. 2A, 2B).
HOXA3 Suppresses Leukocyte Recruitment
to Diabetic Wounds
Because the diabetic wound environment exhibits poor tissue
repair, and is associated with chronic inﬂammation, we
hypothesized that a larger percentage of the BMDCs recruited
to these wounds at day 7 were leukocytes, compared with
nondiabetic mice. Not surprisingly, as shown in Figure 3,
double labeling of GFP and Cd45 (a pan-leukocyte marker)
revealed that although diabetic mice have similar numbers of
inﬂammatory cells at day 0, they showed a ﬁvefold increase
in GFP
þCd45
þ leukocytes in day 7 wounds and a twofold
increase in day 14 wounds compared with nondiabetic con-
trols (Fig. 3A, 3B). This is consistent with previous reports
that demonstrate both increased numbers and retention time
of inﬂammatory cells in skin after injury in diabetic mice
compared with nondiabetic mice [15, 16].
Furthermore, based on our results demonstrating that
HOXA3 gene transfer resulted in an overall reduction in the
number of BMDCs, we wished to test whether sustained
expression of HOXA3 might result in a reduction in the num-
ber of leukocytes recruited to the wound, and perhaps pro-
mote healing by suppressing the chronic inﬂammation associ-
ated with diabetic wounds. We found CMV-HOXA3 treatment
signiﬁcantly reduced the number of GFP
þCd45
þ leukocytes
present in the wound area at days 7 and 14 after wounding
compared with empty vector control-treated mice (Fig. 3A,
3B). However, ﬂow cytometry analysis of cleared (RBC-
lysed) peripheral blood at days 0, 4, and 7 revealed that there
was no signiﬁcant difference in circulating GFP
þCd45
þ cells
Mace, Restivo, Rinn et al. 1657
www.StemCells.comat any of the assayed time points (data not shown), suggesting
that the reduction of leukocytes in the wounds of HOXA3-
treated diabetic mice was due to speciﬁcally suppressing leu-
kocyte recruitment to the wound or retention at the wound
site, rather than a reduction in mobilization from the bone
marrow.
HOXA3 Expression in Diabetic Wounds Stimulates
Bone Marrow Mobilization and Recruitment
of EPCs
Because HOXA3 strongly stimulates neovascularization in the
wound [3], we also investigated whether EPC recruitment to
the wound was inﬂuenced. Immunolocalization of EPCs was
performed using double and/or triple labeling of antibodies
against GFP, Cd133, and Cd34. The antibody combination
detecting GFP, Cd133, and Cd34 marks a population of very
early EPCs, whereas the GFP
þCd34
þCd133
  cells are
regarded as more mature EPCs [28, 29]. Despite the reduction
in total BMDCs and Cd45
þ cells shown in Figure 3, db/db
mice treated with CMV-HOXA3 displayed a signiﬁcant
increase in GFP
þCd34
þ EPCs in wounds at day 7 compared
with vector control-treated db/db (Fig. 4A, 4B). This relative
increase was still present at day 14, although to a much
reduced extent (not shown). Cd133 was not detectable in the
wound tissue, suggesting that cells retained in the wound
were more mature EPCs. Additionally, because multipotent
MSCs can express Cd34 and can also be recruited from the
bone marrow, as well as surrounding adipose tissue, and con-
tribute to angiogenesis we could not rule out that some of
these cells were MSCs as opposed to ‘‘classic’’ EPCs [30]. To
detect non-BM-derived MSCs, we used a combination of
Cd29 (integrin b-1), which murine MSCs consistently express,
Cd45, which MSCs consistently do not express [30], and GFP
to mark cells derived from the bone marrow (this was also
negatively selected against). We found no difference in non-
BM-derived MSC recruitment between HOXA3-treated and
control-treated wounds (data not shown).
To test whether the differences in EPCs present in
HOXA3-treated wounds at day 7 were due to enhanced EPC
recruitment, and/or could be attributed to increased mobiliza-
tion of EPCs from the bone marrow, we analyzed blood sam-
ples collected both from db/db mice treated with CMV-
HOXA3 or control plasmid, as well as db/þ mice treated with
control plasmid. Flow cytometry was performed to analyze
cleared peripheral blood samples using GFP, Cd34, and
Cd133 as markers of EPCs at the following time points: day
0, day 4, day 7, and day 14. Although there were no signiﬁ-
cant differences in GFP
þCd34
þCd133
  cells (more mature
EPCs), ‘‘early’’ EPCs (GFP
þCd34
þCd133
þ cells) showed a
signiﬁcant increase in circulation in CMV-HOXA3-treated db/
db mice compared with controls at days 4 and 7 after injury
(Fig. 4C--4F). Thus HOXA3 functions not only to reduce
inﬂammatory cell inﬁltration into wounds, but also to selec-
tively mobilize and recruit EPCs, and possibly BM-derived
Cd34
þ MSCs to wounds, promoting healing.
Analysis of Cell-Speciﬁc Transgene Expression
Because changes in Hox gene expression have been shown to
have dramatic effects on bone marrow-derived progenitor
cells, including increasing proliferation and self-renewal in
the stem cell compartment (recently reviewed in Argiropoulos
and Humphries [17]), we evaluated whether local gene trans-
fer of HOXA3 to wounds could also result in transfection of
circulating cells or bone marrow-resident cells, and thus alter
their fate. Quantitative PCR analyses using primer sets spe-
ciﬁc to the human HOXA3 transgene revealed that although
the HOXA3 transgene was easily detectable in wound tissue 4
days after gene transfer, it was not detectable in peripheral
blood or bone marrow (Fig. 5A). Accordingly, levels of en-
dogenous Hoxa3 expression were similar in circulating cells
and bone marrow cells of HOXA3-treated and vector control-
treated animals (Fig. 5B). We next investigated whether
recruited BMDCs, in particular leukocytes (Cd45
þ) and/or
EPCs (Cd34
þ) cells, were transfected by application of trans-
gene to the wound, thus affecting their behavior within the
wound. To avoid problems with detection of endogenous
Hoxa3, we performed a gene transfer experiment using CMV-
GFP. As shown in Figure 5C, expression of the transgene in
wounds at day 4 is overwhelmingly biased toward leukocytes,
suggesting that the largest effect of HOXA3 gene transfer to
Figure 2. Expression of HOXA3 during diabetic wound repair modulates the recruitment of bone marrow-derived cells (BMDCs). (A): Repre-
sentative images of wound sections from diabetic mice with GFP immunoﬂuorescent detection of BMDCs at days 0, 7, and 14 following wound-
ing, treated with control (empty vector) or CMV-HOXA3 plasmid. Scale bar ¼ 100 lm. (B): Relative number of BMDCs (normalized against
40,6-diamidino-2-phenylindole [DAPI]-stained nuclei) in wounds from diabetic mice treated with control (DBþcntl) or CMV-HOXA3 plasmid
(DBþA3) at day 0, day 7, and day 14 following wounding. Asterisk indicates p < .05. Abbreviations: DBþA3, diabetic wound treated with
CMV-HOXA3;d b þA3 D7, diabetic wound treated with CMV-HOXA3 at day 7; dbþA3 D14, diabetic wound treated with CMV-HOXA3 at day
14; DBþcntl, diabetic wound treated with control; dbþcntl D7, diabetic wound treated with control at day 7; dbþcntl D14, diabetic wound
treated with control at day 14; db D0, diabetic wound at day 0; GFP, green ﬂuorescent protein.
1658 Wound Recruitment of Bone Marrow-Derived Cellswounds is due to direct HOXA3-mediated changes in leuko-
cyte behavior.
Microarray Analyses of HOXA3-Mediated Changes
in Wound Tissue Gene Expression
To investigate how HOXA3 expression in wound tissue alters
gene expression to control selective recruitment of BMDC
populations, we used MEEBO arrays (see Materials and
Methods) to identify differentially expressed genes in cutane-
ous wounds from db/db mice treated with either CMV-
HOXA3 or control plasmid. We chose day 4 as the time point
to harvest the wounds for RNA isolation, as this day repre-
sents the transition from inﬂammatory to proliferative phase
and precedes the observed differences in BMDC mobilization
and recruitment at day 7 (Fig. 6A).
Day 4 wounds treated with CMV-HOXA3 showed signiﬁ-
cant differential expression of 837 known genes by at least
Figure 3. Expression of HOXA3 in diabetic wounds suppresses inﬂammatory cell recruitment. (A): Representative images of sections from day 0,
7, and 14 wounds from nondiabetic and diabetic mice treated with control or CMV-HOXA3 plasmid. Upper panels of each group show GFP
þ cells
and lower panels show Cd45
þ cells. Scale bar ¼ 100 lm. (B): Bar graphs showing normalized relative numbers of GFP
þ and GFP
þCd45
þ (leuko-
cyte) cells recruited to the wounds at days 0, 7, and 14 in nondiabetic and diabetic mice treated with control or CMV-HOXA3 plasmid. Abbreviations:
D0, day 0; D7, day 7; D14, day 14; dbþA3, diabetic wound treated with CMV-HOXA3;d b þA3 D7, diabetic wound treated with CMV-HOXA3 at
day 7; dbþA3 D14, diabetic wound treated with CMV-HOXA3 at day 14; dbþC and dbþc, diabetic wound treated with control; db D0, diabetic
wound at day 0; db D7, diabetic wound at day 7; db D14, diabetic wound at day 14; GFP, green ﬂuorescent protein; hcþc, heterozygous control þ
control plasmid; non-db D0, nondiabetic wound at day 0; non-db D7, nondiabetic wound at day 7; non-db D14, nondiabetic wound at day 14.
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www.StemCells.com1.5-fold (p < .05), with 505 genes downregulated and 332
genes upregulated in response to CMV-HOXA3 treatment
(Fig. 6A, supporting information data 1 and 2; complete data
ﬁles have been deposited at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc¼GSE13324). Analyses of the HOXA3-
repressed gene set revealed regulatory pathways inhibited by
HOXA3. Seven of these pathways are speciﬁc to leukocyte
signaling and differentiation (Table 1, left-hand column, high-
lighted pathways), consistent with our ﬁndings that HOXA3
suppresses the inﬂammatory response. In particular, many
members of the nuclear factor jB (NF-jB) pathway were
repressed, including interleukin 1 alpha, Tnf receptor-associ-
ated factor 1, interleukin-1 receptor-associated kinase 2, mye-
loid differentiation primary response gene 88, toll-interacting
protein, TNFAIP3-interacting protein 1, B-cell leukemia/lym-
phoma 10, and NF-jB inhibitor-interacting Ras-like protein 2
(Fig. 6B). Because of their central role in NF-jB signaling in
inﬂammatory cells, Myd88 and Tollip were selected for fur-
ther analysis and validated using qRT-PCR (Fig. 6C). We
also analyzed Tnf-a expression, as it is one of the major tar-
gets of NF-jB activation. Not surprisingly, mice treated with
HOXA3 showed reduced Tnf-a transcriptional activation at
Figure 4. Expression of HOXA3 in diabetic wounds stimulates mobilization of endothelial progenitor cells (EPCs). (A): Representative images
of wound sections from nondiabetic mice (non-db) and diabetic mice (db) treated with control (empty vector) or CMV-HOXA3 plasmid. Upper
panels show GFP
þ bone marrow-derived cells at day 7 and lower panels show Cd34
þ cells. Scale bar ¼ 100 lm. (B): Percentage of total GFP
þ
cells that are double positive for Cd34 recruited to the wound at day 7 in nondiabetic mice treated with control plasmid, and diabetic mice treated
with control (dbþcntl) or CMV-HOXA3 (dbþA3) plasmid. (C): Representative scatter plots of cleared peripheral blood from diabetic GFP chime-
ras at day 4 following wounding treated with control (db2þc) or CMV-HOXA3 (db7þA3) plasmid. Cells in the upper right quadrant are
GFP
þCd133
þCd34
þ (early EPC) cells. (D): Quantiﬁcation of early EPCs in peripheral blood at day 4 following wounding of control-treated or
CMV-HOXA3-treated diabetic wounds. (E): Representative scatter plots of cleared peripheral blood from diabetic GFP chimeras at day 7 follow-
ing wounding treated with control (db2þc) or CMV-HOXA3 (db7þA3) plasmid. Cells in the upper right quadrant are GFP
þCd133
þCd34
þ (early
EPC) cells. (F): Quantiﬁcation of early EPCs in peripheral blood at day 7 following wounding of control-treated or CMV-HOXA3-treated diabetic
wounds. Abbreviations: APC, allophycocyanin; dbþA3 D7, diabetic wound treated with CMV-HOXA3 at day 7; dbþa3 and dbþA3, diabetic
wound treated with CMV-HOXA3 at day 3; dbþC, diabetic wound treated with control; dbþcntl, diabetic wound treated with control; dbþcntl
D7, diabetic wound treated with control at day 7; db1þC, diabetic wound 1 treated with control; db2þC, diabetic wound 2 treated with control;
db7þA3, diabetic wound treated with CMV-HOXA3 at day 7; FMO, ﬂuorescence minus one control; GFP, green ﬂuorescent protein; non-db D7,
nondiabetic wound at day 7; non db, nondiabetic wound; PB, peripheral blood; PE, phycoerythrin.
1660 Wound Recruitment of Bone Marrow-Derived Cellsboth day 4 (p ¼ .078) and day 7 (p ¼ .056) (Fig. 6D). This
HOXA3-mediated repression of proinﬂammatory genes at day
4 is not due to a decrease in the number of inﬂammatory cells
present in the wound at day 4, as the numbers of GFP
þCd45
þ
cells in the wound at day 4 did not signiﬁcantly differ
between HOXA3-treated and control-treated db/db wounds at
this time point (data not shown). All together, these data sug-
gest that HOXA3 suppresses the exacerbated inﬂammatory
cell response found in diabetic chronic wounds in part by
silencing the NF-jB pathway in cells in the wound by day 4,
resulting in a signiﬁcant reduction of inﬂammatory cells in
the wound by day 7, coinciding with the peak of the neovas-
cularization phase.
Analyses of the much smaller set of upregulated genes in
db/db wounds at day 4 did not reveal any KEGG pathways
that are speciﬁc to neovascularization, per se, however several
of the pathways promoted by HOXA3 are known to contrib-
ute to neovascularization, and in particular, to endothelial cell
migration (Table 1, right column, highlighted in yellow), such
as calcium signaling, glycan biosynthesis, and vascular endo-
thelial growth factor (VEGF) signaling pathway components.
GO function analyses of this gene set suggest HOXA3 pro-
motes cell-cell signaling pathways and neurophysiological
processes (Table 1, right column, highlighted in yellow), both
of which have also been shown to play a signiﬁcant role in
neovascularization (reviewed in Lok et al [31] and Scott et al
[32]). However, because HOXA3 has been previously shown
to promote angiogenesis and endothelial cell migration, we
chose to focus on factors from this gene set that directly pro-
mote EPC mobilization and EPC/endothelial cell migration
(Fig. 6E). Although we did not detect any changes in Vegf
expression, chemoattractant molecules monocyte
Figure 5. The HOXA3 transgene is not expressed in peripheral blood or bone marrow cells and has no effect on endogenous Hoxa3. (A): Quan-
titative reverse-transcription polymerase chain reaction (RT-PCR) of RNA isolated from wound tissue, peripheral blood, and bone marrow from
diabetic mice treated with control or CMV-HOXA3 plasmid showing relative expression of the HOXA3 transgene at day 4 following wounding.
(B): Quantitative RT-PCR of RNA isolated from wound tissue from diabetic mice treated with control or CMV-HOXA3 plasmid showing relative
expression of endogenous Hoxa3. (C): Analysis of transgene expression 4 days after wounding and gene transfer. Transgene expression is shown
in green in the upper left panel, white arrowhead indicates expression in hair follicle cells, yellow arrowhead indicates expression in basal kerati-
nocytes, and red arrowhead indicates expression in leukocytes. Leukocytes are marked with red (Cd45) in upper middle panel, and Cd34
þ cells
are shown blue in upper right panel. Lower panels show merged channels as indicated. Scale bar ¼ 100 lm. Abbreviations: þA3, plus HOXA3;
BM, bone marrow; cntl, control; PB, peripheral blood; Tg, transgene; Wnd, wound tissue.
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wound site. (A): Schematic representation of microarray experiment. Mice were split into two groups; unwounded skin was harvested at day 0
and wounded skin, at day 4. Gene expression proﬁles of control-treated and HOXA3-treated wounds were compared. (B): NF-jB pathway mem-
ber gene expression analysis in response to CMV-HOXA3 treatment. (C): Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
validation of selected genes that are central to NF-jB pathway signal transduction. (D): qRT-PCR of Tnfa expression in control-treated and
CMV-HOXA3-treated wounds at days 0, 4, and 7. (E): Proangiogenic gene expression analysis in response to CMV-HOXA3 treatment of diabetic
wounds. (F): qRT-PCR validation of selected genes known to promote endothelial progenitor cell (EPC) mobilization and recruitment to sites of
neovascularization. (G): Model of HOXA3 function during wound repair. Expression of HOXA3 in diabetic wounds results in downregulation of
members of the NF-jB pathway, leading to a decrease in Tnf-a expression. This results in reduced inﬂammation and a wound environment more
conducive to repair and vascular regeneration. Abbreviations: þA3, plus HOXA3; cntl, control; downreg, downregulation; NF-jB, nuclear factor
jB; qPCR, quantitative polymerase chain reaction; TNF-a, tumor necrosis factor a; upreg, upregulation.chemoattractant protein-1 (MCP-1/Ccl2) and Defb15, both
potent inducers of EPC mobilization and recruitment [33, 34],
were independently conﬁrmed by quantitative PCR (Fig. 6F).
Interestingly, Lrp1, which is both proangiogenic [35, 36] and
anti-inﬂammatory, via inhibition of the NF-jB pathway [37],
was also increased (Fig. 6E).
All together, these data suggest that HOXA3 acts within
wound tissue to increase expression of angiogenic and EPC
recruiting factors, while also repressing expression of genes
that contribute to inﬂammatory cell activation and recruit-
ment, resulting in enhanced neovascularization and tissue
repair. Suppression of the NF-jB pathway by HOXA3 results
in a reduction of TNF-a and inﬂammation, which are associ-
ated with the chronic wound environment and reduced
HOXA3 expression characteristic of diabetic wounds. This
‘‘rescue’’ of the chronic wound environment is, in turn, asso-
ciated with enhanced neovascularization (Fig. 6G).
DISCUSSION
In this study we have demonstrated that sustained expression of
HOXA3 in diabetic wounds signiﬁcantly alters BMDC recruit-
ment in response to wounding. We show that local expression
of HOXA3 in wound tissue not only results in increased mobili-
zation and recruitment of EPCs, but also suppresses the exces-
sive inﬂammatory response characteristic of diabetic wounds.
Together, the enhanced angiogenic response and reduced
inﬂammation lead to a signiﬁcant acceleration of healing.
Previous attempts to improve healing in diabetic wounds
have focused either on improving angiogenesis via direct acti-
vation and/or enhancing recruitment of EPCs, or reducing ex-
cessive inﬂammation, and have met with various degrees of
success [24, 38–40]. Reduced angiogenesis in diabetic wounds
has been attributed to reduced mobilization, function, and
engraftment of EPCs into tissues [39, 41]. However, direct
application of SDF-1/CXCL12 enhances mobilization of
EPCs and improves healing, speciﬁcally enhancing recruit-
ment of Cd34
þ EPCs into the neovasculature of granulation
tissue [39, 42]. In the current study we have shown that
HOXA3 induces expression of MCP-1/Ccl2, a related member
of the CxC/CC chemokine family that has previously been
shown to directly recruit EPCs [43] and stimulate angiogene-
sis [44]. Although we did not detect any differences in VEGF
expression itself, reduced VEGF signaling, as well as aberrant
cell adhesion properties of EPCs to endothelial cells in dia-
betic wounds, also contributes to poor EPC recruitment and
retention [45–47]. VEGF itself has been shown sufﬁcient for
recruitment and retention of recruited bone marrow-derived
circulating cells in wild type mice [5]. VEGF can accelerate
wound healing when topically applied to diabetic wounds by
promoting angiogenesis and recruitment of Tie2
þ EPCs [47].
However, VEGF and other growth factor therapy in patients
has proven less successful than expected, most likely due to
high levels of proteases and advanced glycation end products
(AGEs), both of which are associated with excessive inﬂam-
mation in the diabetic wound environment [16, 48]. High lev-
els of glucose can react nonenzymatically with the amino
groups of proteins (glycation). One consequence of this is
reduced effectiveness of downstream components of the
VEGF signaling pathway [49]. Thus, treatment of damaged
tissue, even with high levels of ligand, is ineffective. Further-
more, AGE-modiﬁed ﬁbronectin signiﬁcantly reduced EPC
attachment [50], whereas blockade of the receptor for AGE
signiﬁcantly improved vascularization in diabetic mice [16].
Our ﬁndings that peripheral blood of HOXA3-treated animals
contained greater numbers of immature Cd34
þCd133
þ EPCs,
whereas wounds contained predominantly more mature
Cd34
þCd133
  EPCs, suggest that HOXA3 not only increased
mobilization of immature EPCs but also created an
Table 1. Regulatory pathways modulated by HOXA3 during
wound repair
KEGG pathway (no.)
Repressed by HOXA3 Activated by HOXA3
MAPK signaling pathway (15) Calcium signaling pathway (5)
Regulation of actin
cytoskeleton (13)
Glycan structures-biosynthesis
(5)
Wnt signaling pathway (10) Purine metabolism (4)
Purine metabolism (10) Alzheimer’s disease (4)
Neuroactive ligand-receptor
interaction (10)
Long-term potentiation (4)
Calcium signaling pathway (9) Cell cycle (4)
Cytokine-cytokine receptor
interaction (9)
Tyrosine metabolism (3)
Focal adhesion (8) Tryptophan metabolism (3)
Natural killer cell mediated
cytotoxicity (7)
VEGF signaling pathway (3)
Apoptosis (7) Arachidonic acid metabolism (3)
Tight junction (7) GnRH signaling pathway (3)
Insulin signaling pathway (7)
Colorectal cancer (6)
Leukocyte transendothelial
migration (6)
Long-term depression (6)
Gap junction (6)
Adherens junction (5)
VEGF signaling pathway (5)
Axon guidance (5)
Cell adhesion molecules
(CAMs) (5)
B cell receptor signaling
pathway (5)
T cell receptor signaling
pathway (5)
GnRH signaling pathway (4)
Cell cycle (4)
Long-term potentiation (4)
Neurodegenerative Disorders (4)
Pyrimidine metabolism (4)
Oxidative phosphorylation (4)
Toll-like receptor signaling
pathway (4)
Alanine and aspartate
metabolism (3)
Sphingolipid metabolism (3)
Pyruvate metabolism (3)
Notch signaling pathway (3)
Type I diabetes mellitus (3)
Alzheimer’s disease (3)
GO process (no.)
Repressed by HOXA3 Activated by HOXA3
Morphogenesis (32) Neurophysiological process (35)
Cell cycle (25) Cell-cell signaling (10)
Cell death (22)
Cell development (16)
Positive regulation of enzyme
activity (10)
Regulation of transferase
activity (10)
Myeloid cell differentiation (6)
Muscle contraction (5)
Appendage development (4)
Spermatid differentiation (3)
Molting cycle (3)
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sion and subsequent maturation of the recruited EPCs. This
environment may have also stimulated additional stem/pro-
genitor cells not derived from the bone marrow, and thus not
detectable by our GFP tracking methods, as these studies are
based on cells derived from reconstituted bone marrow cells
descended from hematopoietic stem cells.
Chronic wounds also exhibit high levels of proteases that can
modify the provisional extracellular matrix necessary for proper
EPC adhesion [51, 52]. The high levels of proteases present in di-
abetic and chronic wounds have been linked to excessive inﬂam-
mation with recruited neutrophils and macrophages expressing
high levels of a variety of matrix-degrading proteins [15]. A role
for limiting inﬂammation in improving tissue repair is also sup-
ported by studies in Pu.1-null mice that lack neutrophils and mac-
rophages. These mice healed faster and displayed no evidence of
ﬁbrosis compared with their wild type counterparts [14]. Impor-
tantly, in diabetic wounds, neutralization of TNF-a activity
resulted in improved repair and healing due to inactivation of
macrophages [40], and our present results show that in addition
to improving EPC recruitment, HOXA3 also attenuates the TNF
pathway, reducing inﬂammation. Speciﬁcally we show that
HOXA3 inhibitshyperactivation of the NF-jB pathway, resulting
in attenuation of Tnf-a expression, and leading to an overall
reduction in Cd45
þ leukocytes within the diabetic wound tissue.
Myd88 and Tollip, both signiﬁcantly downregulated by HOXA3
treatment, encode central components of the NF-jB pathway,
functioning as adaptor proteins required for most Toll-like recep-
tor activation of NF-jB in both wound-resident cells and
recruited BMDCs. Interestingly, complete loss of Myd88 func-
tion, however, results in impaired wound healing and poor neo-
vascularization [53]. Thus it seems that the correct balance of
NF-jB activation must be achieved for efﬁcient repair and regen-
eration. Concentration-dependent differential gene regulation by
activated NF-jB is well documented (reviewed in Stathopoulos
and Levine [54] and Sur et al [55]). We speculate that high levels
of nuclear NF-jB result in transcription of genes promoting
recruitment/retention of leukocytes, whereas moderate levels of
nuclear NF-jB do not, thus facilitating healing.
Differential Recruitment of EPCs and Leukocytes?
The majority of EPCs as well as inﬂammatory cells recruited to
the wound are derived form stem/progenitor populations within
the bone marrow. However, it is not clear how different popula-
tions within the bone marrow are differentially mobilized. For
example, MCP-1/Ccl2 can mobilize EPCs and monocyte popu-
lations. Although application of this factor has been linked to
improved repair and increased EPC recruitment, Ccl2-null mice
also displayed reduced inﬂammation and skin ﬁbrosis after
wounding [56]. Thus the precise mechanisms that allow for
enhanced EPC recruitment but restrict leukocyte retention in
HOXA3-treated wounds are not clear. Whether enhanced EPC
recruitment accelerates vascular maturation and stability, which
in turn would reduce leukocyte extravasation, is not known.
One possibility is that attenuated NF-jB activity results in a
switch in phenotype of the recruited monocytes, resulting in
their differentiation into endothelial cells or endothelial support
cells instead of activated macrophages. This idea is supported
by studies demonstrating that hematopoietic progenitor cell dif-
ferentiation into an activated dendritic cell can be blocked by
VEGF receptor activation on the progenitor cell and requires in-
hibition of NF-jB [57]. Furthermore, environmental cues, such
as continued proangiogenic stimulation by factors such as
VEGF, promote the differentiation of monocytic progenitor
cells into endothelial-like cells [58]. Future studies will be
focused on elucidating the precise gene regulatory networks
downstream of HOXA3 function controlling the recruitment
and behavior of EPCs to sites of injury.
SUMMARY
This study indicates that the ability of HOXA3 to activate
multiple linked pathways to improve angiogenesis and EPC
recruitment, as well as suppressing inﬂammatory pathways
that can inhibit repair and regeneration, comprises a truly suc-
cessful therapy for diabetic chronic wounds. HOXA3 acts as
a ‘‘master control’’ transcription factor that sits at the top of a
large transcriptional regulatory network, and affects a variety
of pathways that regulate these processes in a developmental
context [59]. It is tempting to speculate that restoring expres-
sion of ‘‘master morphoregulatory factors’’ important during
embryonic development may signiﬁcantly contribute to tissue
repair therapies in adults, and perhaps provide a key to
unlocking the potential for true tissue regeneration.
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